Suggested remit: To appraise the clinical and cost effectiveness of selinexor with bortezomib and low-dose dexamethasone within its marketing authorisation for treating relapsed refractory multiple myeloma.
 
Status In progress
Process STA 2018
ID number 3797

Provisional Schedule

Assessment report sent for information 17 August 2022

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
29 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
25 August 2020 - 23 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 November 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance